Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Qiagen to EUR 49 from EUR 50 and keeps an Overweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on QGEN:
- Qiagen price target lowered to $48 from $50 at UBS
- Qiagen sees FY23 EPS at least $2.07 , consensus $2.11
- Qiagen reports Q2 EPS 51c, consensus 50c
- QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
- QGEN Earnings this Week: How Will it Perform?